English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 18076/20274 (89%)
造訪人次 : 5356125      線上人數 : 1085
RC Version 7.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧:
  • 您可在西文檢索詞彙前後加上"雙引號",以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋,建議至進階搜尋限定作者欄位,可獲得較完整資料
  • 進階搜尋
    請使用永久網址來引用或連結此文件: https://ir.cnu.edu.tw/handle/310902800/34351


    標題: Salvianolic Acid C Protects against Cisplatin-Induced Acute Kidney Injury through Attenuation of Inflammation, Oxidative Stress and Apoptotic Effects and Activation of the CaMKK-AMPK-Sirt1-Associated Signaling Pathway in Mouse Models
    作者: Chien, Liang-Hsuan
    Wu, Chien-Ta
    Deng, Jeng-Shyan
    Jiang, Wen-Ping
    Huang, Wen-Chin
    Huang, Guan-Jhong
    貢獻者: China Med Univ, Coll Chinese Med, Dept Chinese Pharmaceut Sci & Chinese Med Resourc
    Kaohsiung Med Univ, Coll Pharm, Fac Pharm
    Asia Univ, Dept Hlth & Nutr Biotechnol
    Chia Nan Univ Pharm & Sci, Dept Pharm
    China Med Univ, Grad Inst Biomed Sci, Sch Med
    China Med Univ, Sch Med, Int Masters Program Biomed Sci
    關鍵字: salvianolic acid C
    cisplatin
    acute kidney injury
    anti-inflammation
    oxidative stress
    apoptosis
    CaMKK-AMPK-Sirt1 pathway
    日期: 2021
    上傳時間: 2023-11-11 11:45:23 (UTC+8)
    出版者: MDPI
    摘要: Acute kidney injury (AKI) is a sudden reduction in kidney activity and has a high mortality rate. Salvianolic acid C (SAC), one of the main polyphenolic components of Salvia miltiorrhiza, displays significant pharmacologically active effects. An animal model of cisplatin-induced kidney injury was used to study the potential of SAC to improve AKI. First, SAC was administered intraperitoneally in mice for 10 consecutive days, and then cisplatin was administered intraperitoneally on day 7 to establish a nephrotoxicity mouse model. SAC mitigated renal histological changes, blood creatinine (CRE) and blood urea nitrogen (BUN) production and the levels of inflammatory mediators in the cisplatin-induced AKI. Furthermore, malondialdehyde (MDA) levels were reduced and glutathione (GSH) was increased after intraperitoneal injection (i.p.) administration of SAC. In addition, based on Western blot data, SAC reduced the expression of inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), nuclear factor kappa B (NF-kappa B) and mitogen-activated protein kinase (MAPK) activation in mouse renal tissues. Finally, SAC diminished the level of TLR-4 expression and enhanced the production of several antioxidative enzymes (superoxidase dismutase (SOD1), glutathione peroxidase (GPx3), catalase, nuclear-factor-erythroid-2-related factor 2 (Nrf2) and heme oxygenase 1 (HO-1)), Sirtuin 1 (Sirt1), p-AMP-activated protein kinase (AMPK) and p-Ca2+/calmodulin-dependent protein kinase kinase (CaMKK). In addition, Sirt1 inhibition (EX 527) inverted the effect of SAC against cisplatin-induced nephrotoxicity. Collectively, SAC provides a therapeutic target with promising clinical potential after cisplatin treatment by attenuating oxidative stress and inflammation.
    關聯: ANTIOXIDANTS-BASEL, v.10, n.10, pp.1620
    顯示於類別:[藥學系(所)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    antiox10101620.pdf38715KbAdobe PDF122檢視/開啟
    index.html0KbHTML242檢視/開啟


    在CNU IR中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋